ZNF609

Summary

ZNF609 (zinc finger protein 609, HGNC:29003) is a protein-coding gene on chromosome 15q22.1, encoding Zinc finger protein 609 (O15014). Transcription factor, which activates RAG1, and possibly RAG2, transcription.

Predicted to enable promoter-specific chromatin binding activity. Involved in regulation of myoblast proliferation. Located in nucleoplasm.

Source: NCBI Gene 23060 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 232 total
• MANE Select transcript: NM_015042

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29003
Approved symbol	ZNF609
Name	zinc finger protein 609
Location	15q22.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0295
Ensembl gene	ENSG00000180357
Ensembl biotype	protein_coding
OMIM	617474
Entrez	23060

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000326648, ENST00000416172, ENST00000558680, ENST00000559364, ENST00000925215, ENST00000925216

RefSeq mRNA: 1 — MANE Select: NM_015042 NM_015042

CCDS: CCDS32270

Canonical transcript exons

ENST00000326648 — 10 exons

Exon	Start	End
ENSE00001249288	64680646	64680862
ENSE00001249293	64680185	64680360
ENSE00001249301	64678116	64678482
ENSE00001249308	64681309	64681387
ENSE00001249311	64673916	64676256
ENSE00001484299	64681692	64686068
ENSE00001484308	64499293	64500166
ENSE00003459229	64622827	64623052
ENSE00003665263	64670346	64670433
ENSE00003932992	64460578	64460838

Expression profiles

Bgee: expression breadth ubiquitous, 231 present calls, max score 93.54.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.8839 / max 197.0913, expressed in 1767 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
147176	8.3877	1746
147177	1.6801	976
147178	0.8161	445

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	93.54	gold quality
colonic epithelium	UBERON:0000397	92.60	gold quality
ganglionic eminence	UBERON:0004023	91.38	gold quality
cortical plate	UBERON:0005343	90.64	gold quality
calcaneal tendon	UBERON:0003701	87.85	gold quality
tendon	UBERON:0000043	86.83	gold quality
medial globus pallidus	UBERON:0002477	86.46	gold quality
buccal mucosa cell	CL:0002336	85.80	gold quality
adrenal tissue	UBERON:0018303	85.57	gold quality
left ovary	UBERON:0002119	84.86	gold quality
tendon of biceps brachii	UBERON:0008188	84.71	gold quality
stromal cell of endometrium	CL:0002255	84.23	gold quality
globus pallidus	UBERON:0001875	84.19	gold quality
right ovary	UBERON:0002118	84.18	gold quality
embryo	UBERON:0000922	83.56	gold quality
secondary oocyte	CL:0000655	83.26	gold quality
lower esophagus muscularis layer	UBERON:0035833	83.00	gold quality
lower esophagus	UBERON:0013473	82.99	gold quality
islet of Langerhans	UBERON:0000006	82.69	gold quality
mucosa of stomach	UBERON:0001199	82.69	gold quality
ovary	UBERON:0000992	82.65	gold quality
pancreatic ductal cell	CL:0002079	82.60	silver quality
inferior olivary complex	UBERON:0002127	82.54	gold quality
sural nerve	UBERON:0015488	82.53	gold quality
body of uterus	UBERON:0009853	82.45	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	82.10	gold quality
right uterine tube	UBERON:0001302	81.94	gold quality
smooth muscle tissue	UBERON:0001135	81.78	gold quality
leukocyte	CL:0000738	81.77	gold quality
monocyte	CL:0000576	81.69	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.62
E-CURD-112	no	2.85

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

383 targeting ZNF609, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939

Literature-anchored findings (GeneRIF, showing 9)

• these findings illustrated that cir-ZNF609 took part in the onset of HSCR through the crosstalk with AKT3 by competing for shared miR-150-5p. (PMID:27903978)
• Circular RNA circ-ZNF609 is associated with heavy polysomes, and it is translated into a protein in a splicing-dependent and cap-independent manner, resulting in a protein that controls myoblast proliferation. (PMID:28344082)
• our current study reveals the role of the circ-ZNF609/miR-138-5p/FOXP4 regulatory network in renal carcinoma and provides a new perspective for the pathogenesis of renal carcinoma. (PMID:30478938)
• CircRNA ZNF609 promotes growth and metastasis of nasopharyngeal carcinoma by competing with microRNA-150-5p. (PMID:31002133)
• Circ-ZNF609 promotes carcinogenesis of gastric cancer cells by inhibiting miRNA-145-5p expression. (PMID:31773689)
• CircRNA ZNF609 promotes angiogenesis in nasopharyngeal carcinoma by regulating miR-145/STMN1 axis. (PMID:33943007)
• YY1 and eIF4A3 are mediators of the cell proliferation, migration and invasion in cholangiocarcinoma promoted by circ-ZNF609 by targeting miR-432-5p to regulate LRRC1. (PMID:34898474)
• A protein encoded by circular ZNF609 RNA induces acute kidney injury by activating the AKT/mTOR-autophagy pathway. (PMID:36110046)
• CircZNF609 inhibits miR-150-5p to promote high glucose-induced damage to retinal microvascular endothelial cells. (PMID:38679361)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf609a	ENSDARG00000103388
danio_rerio	znf609b	ENSDARG00000104530
mus_musculus	Zfp609	ENSMUSG00000040524
rattus_norvegicus	Zfp609	ENSRNOG00000015977
drosophila_melanogaster	sbb	FBGN0285917

Paralogs (1): ZNF608 (ENSG00000168916)

Protein

Protein identifiers

Zinc finger protein 609 — O15014 (reviewed: O15014)

All UniProt accessions (2): O15014, E7ERY8

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor, which activates RAG1, and possibly RAG2, transcription. Through the regulation of RAG1/2 expression, may regulate thymocyte maturation. Along with NIPBL and the multiprotein complex Integrator, promotes cortical neuron migration during brain development by regulating the transcription of crucial genes in this process. Preferentially binds promoters containing paused RNA polymerase II. Up-regulates the expression of SEMA3A, NRP1, PLXND1 and GABBR2 genes, among others. Involved in the regulation of myoblast proliferation during myogenesis.

Subunit / interactions. Interacts (via N-terminus) with NIPBL. Interacts with INTS13; promoting association with the integrator complex.

Subcellular location. Nucleus Nucleus.

Tissue specificity. Isoform 1: Expressed in myoblasts and myotubes. Isoform 2: Expressed in myoblasts and myotubes, with a preference in undifferentiated myoblasts.

Induction. Isoform 1: Up-regulated during neuronal differentiation in retinoic acid-treated SH-SY5Y cells. Isoform 2: Down-regulated during myogenesis.

Miscellaneous. Produced by a back-splicing reaction which joins the 5’-splice site of the first coding exon with the 3’-splice site of the upstream intron resulting in a circular RNA, called circ-ZNF609. The translation starts with the same initiator methionine as that of the linear transcript encoding isoform 1. The stop codon is created upon circularization.

Isoforms (2)

UniProt ID	Names	Canonical?
O15014-1	1	yes
O15014-2	2

RefSeq proteins (1): NP_055857* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR040010	ZN608/ZN609	Family

UniProt features (63 total): modified residue 22, compositionally biased region 19, region of interest 8, cross-link 5, splice variant 2, mutagenesis site 2, strand 2, chain 1, zinc finger region 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8PK5	X-RAY DIFFRACTION	2.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15014-F1	45.99	0.04

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (27): 358, 361, 379, 381, 413, 433, 446, 452, 467, 470, 533, 576, 578, 743, 746, 758, 804, 823, 842, 846 …

Mutagenesis-validated functional residues (2):

Position	Phenotype
36	abolished interaction with ints13 component of the integrator complex.
37	abolished interaction with ints13 component of the integrator complex.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 216 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_NEUROGENESIS, CACCAGC_MIR138, CTATGCA_MIR153, GTGCCTT_MIR506, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GTGTTGA_MIR505, GOBP_REGULATION_OF_NEURON_MIGRATION, GOBP_NEURON_MIGRATION, GOBP_POSITIVE_REGULATION_OF_NEURON_MIGRATION, CCCAGAG_MIR326, AGTCAGC_MIR345, CCAGGGG_MIR331, CTTTGTA_MIR524

GO Biological Process (5): regulation of transcription by RNA polymerase II (GO:0006357), muscle organ development (GO:0007517), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of myoblast proliferation (GO:2000291), positive regulation of neuron migration (GO:2001224)

GO Molecular Function (4): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), promoter-specific chromatin binding (GO:1990841), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
regulation of DNA-templated transcription	1
animal organ development	1
muscle structure development	1
positive regulation of DNA-templated transcription	1
regulation of cell population proliferation	1
myoblast proliferation	1
neuron migration	1
positive regulation of cell migration	1
regulation of neuron migration	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
transition metal ion binding	1
chromatin binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1100 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF609	SHPRH	Q149N8	732
ZNF609	EIF4G2	P78344	701
ZNF609	MBNL3	Q9NUK0	599
ZNF609	MBNL2	Q5VZF2	592
ZNF609	ANKRD52	Q8NB46	573
ZNF609	HIPK3	Q9H422	565
ZNF609	MBNL1	Q9NR56	564
ZNF609	FOXP4	Q8IVH2	538
ZNF609	YTHDF3	Q7Z739	527
ZNF609	QKI	Q96PU8	512
ZNF609	FBXW7	Q969H0	506
ZNF609	FUS	P35637	488
ZNF609	PABPN1	Q86U42	476
ZNF609	ITCH	Q96J02	466
ZNF609	AKT3	Q9Y243	437

IntAct

142 interactions, top by confidence:

A	B	Type	Score
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
HDAC1	ZNF609	psi-mi:“MI:0914”(association)	0.730
NFIC	NFIB	psi-mi:“MI:2364”(proximity)	0.690
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
RFPL4B	RFPL4A	psi-mi:“MI:0914”(association)	0.640
PIGT	ZNF609	psi-mi:“MI:0914”(association)	0.530
SBSPON	ZNF609	psi-mi:“MI:0914”(association)	0.530
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
FLCN	ZNF609	psi-mi:“MI:0914”(association)	0.530
CLEC11A	VWA8	psi-mi:“MI:0914”(association)	0.530
PIP	TBKBP1	psi-mi:“MI:0914”(association)	0.530
EXOC5	ZNF609	psi-mi:“MI:0914”(association)	0.510
EN1	NFIB	psi-mi:“MI:2364”(proximity)	0.470
Dynll1		psi-mi:“MI:0915”(physical association)	0.400
Magoh	TRAPPC13	psi-mi:“MI:0914”(association)	0.350
PRKCI	TRAPPC13	psi-mi:“MI:0914”(association)	0.350
ATL3	SNX14	psi-mi:“MI:0914”(association)	0.350
HDAC1	TRAK1	psi-mi:“MI:0914”(association)	0.350
INTS14	DKFZP586J0619	psi-mi:“MI:0914”(association)	0.350
USP7	STIL	psi-mi:“MI:0914”(association)	0.350
AUTS2	ZNF609	psi-mi:“MI:0914”(association)	0.350
THSD4	KRBA1	psi-mi:“MI:0914”(association)	0.350
FLCN	AGAP1	psi-mi:“MI:0914”(association)	0.350

BioGRID (173): ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Proximity Label-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS), ZNF609 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IBL7, A2A891, A3RK74, A4L7N3, B5DE09, E1BPQ1, G3V7R4, O15014, O43524, P11420, P15806, P15881, P15884, P15923, P21677, P30985, P51514, P70365, P98180, Q01978, Q12778, Q14135, Q15596, Q15788, Q4PJW2, Q53TQ3, Q60420, Q60722, Q61026, Q61286, Q62655, Q66IY8, Q66JJ0, Q6DIH5, Q6EUW2, Q6NZT6, Q6PCG7, Q7T2G1, Q7ZXS3, Q80V24

Diamond homologs: O15014, Q56A10, Q8BZ47, Q9ULD9, Q9UTH8, P32432, Q5RDF5, Q80ZQ5, Q86VZ6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 165 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RNA Polymerase III Transcription Termination	5	24.1×	4e-04
Deactivation of the beta-catenin transactivating complex	8	18.1×	6e-06
RNA Polymerase III Abortive And Retractive Initiation	5	13.5×	4e-03
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	7	9.9×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
neuron fate specification	5	23.9×	2e-04
cell fate commitment	6	12.1×	9e-04
positive regulation of miRNA transcription	6	11.9×	9e-04
cartilage development	6	10.3×	1e-03
inner ear morphogenesis	5	10.2×	4e-03
anatomical structure morphogenesis	10	9.5×	2e-05
retina development in camera-type eye	5	8.7×	8e-03
somatic stem cell population maintenance	5	8.4×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

232 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	210
Likely benign	4
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

2843 predictions. Top by Δscore:

Variant	Effect	Δscore
15:64526535:G:GT	donor_gain	1.0000
15:64622824:C:G	acceptor_gain	1.0000
15:64622825:A:AG	acceptor_gain	1.0000
15:64622825:AGAT:A	acceptor_gain	1.0000
15:64622826:G:GA	acceptor_gain	1.0000
15:64622826:GAT:G	acceptor_gain	1.0000
15:64622826:GATG:G	acceptor_gain	1.0000
15:64623048:AGATG:A	donor_gain	1.0000
15:64623049:GATG:G	donor_gain	1.0000
15:64623049:GATGG:G	donor_gain	1.0000
15:64623050:ATG:A	donor_gain	1.0000
15:64623051:TG:T	donor_gain	1.0000
15:64623052:GG:G	donor_gain	1.0000
15:64623053:G:GA	donor_loss	1.0000
15:64623053:G:GG	donor_gain	1.0000
15:64623054:T:A	donor_loss	1.0000
15:64640812:G:GT	donor_gain	1.0000
15:64670430:CAAG:C	donor_loss	1.0000
15:64670431:AAGG:A	donor_loss	1.0000
15:64670432:AGGTA:A	donor_loss	1.0000
15:64670433:GGTA:G	donor_loss	1.0000
15:64670434:GT:G	donor_loss	1.0000
15:64670435:T:A	donor_loss	1.0000
15:64673909:T:TA	acceptor_gain	1.0000
15:64673911:CCAA:C	acceptor_loss	1.0000
15:64673912:CAAG:C	acceptor_loss	1.0000
15:64673913:A:AG	acceptor_gain	1.0000
15:64673913:AAG:A	acceptor_gain	1.0000
15:64673914:A:C	acceptor_loss	1.0000
15:64673914:A:G	acceptor_gain	1.0000

AlphaMissense

9230 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:64499498:T:A	W27R	1.000
15:64499498:T:C	W27R	1.000
15:64499499:G:C	W27S	1.000
15:64499500:G:C	W27C	1.000
15:64499500:G:T	W27C	1.000
15:64499505:T:A	I29N	1.000
15:64499507:G:A	G30R	1.000
15:64499507:G:C	G30R	1.000
15:64499508:G:A	G30E	1.000
15:64499513:G:A	G32R	1.000
15:64499513:G:C	G32R	1.000
15:64499513:G:T	G32W	1.000
15:64499514:G:A	G32E	1.000
15:64499514:G:T	G32V	1.000
15:64499520:T:A	L34H	1.000
15:64499520:T:C	L34P	1.000
15:64499523:T:A	I35N	1.000
15:64499523:T:C	I35T	1.000
15:64499523:T:G	I35S	1.000
15:64499526:T:A	I36N	1.000
15:64499526:T:C	I36T	1.000
15:64499526:T:G	I36S	1.000
15:64499528:G:C	D37H	1.000
15:64499529:A:C	D37A	1.000
15:64499529:A:G	D37G	1.000
15:64499529:A:T	D37V	1.000
15:64499530:C:A	D37E	1.000
15:64499530:C:G	D37E	1.000
15:64499532:T:A	L38Q	1.000
15:64499532:T:C	L38P	1.000

dbSNP variants (sampled 300 via entrez): RS1000001346 (15:64642522 A>G), RS1000021495 (15:64622143 T>C), RS1000028472 (15:64665686 G>C), RS1000037287 (15:64685897 C>G), RS1000052779 (15:64573661 C>G), RS1000055093 (15:64535264 G>A), RS1000073415 (15:64545351 A>G), RS1000087406 (15:64481809 A>C), RS1000087831 (15:64528119 T>G), RS1000088012 (15:64592577 A>G), RS1000090437 (15:64685208 T>C), RS1000101056 (15:64629324 G>A,T), RS1000152775 (15:64580666 C>T), RS1000167797 (15:64667008 T>C), RS1000169671 (15:64672828 G>A)

Disease associations

OMIM: gene MIM:617474 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005232_36	Neuroticism	3.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, affects methylation	3
Cisplatin	decreases response to substance, decreases expression	2
Aflatoxin B1	decreases expression, increases methylation	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	increases abundance, decreases expression	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation	1
coumarin	increases phosphorylation	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
abrine	increases expression	1
Leflunomide	increases expression	1
Arsenic	affects methylation	1
Caffeine	decreases phosphorylation	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	increases O-linked glycosylation, decreases activity	1
Lead	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2LV	Abcam HeLa ZNF609 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.